Tai Kamilia, Need Allan G, Horowitz Michael, Chapman Ian M
University of Adelaide, Department of Medicine, Royal Adelaide Hospital, Adelaide, South Australia, Australia.
Nutrition. 2008 Oct;24(10):950-6. doi: 10.1016/j.nut.2008.04.009. Epub 2008 Jul 23.
We investigated the effects of vitamin D treatment on plasma glucose, serum insulin, and insulin sensitivity in vitamin D-deficient individuals without diabetes mellitus.
Thirty-three adults with vitamin D insufficiency (serum 25-hydroxyvitamin D concentration < or = 50 nmol/L) and without diabetes (12 with impaired glucose tolerance) were given two oral doses of 100 000 IU of cholecalciferol, 2 wk apart. Before the first dose and 2 wk after the second dose, a 75-g oral glucose tolerance test was performed. Plasma glucose, serum insulin, 25-hydroxyvitamin D, and parathyroid hormone concentrations were measured and insulin sensitivity was calculated from the oral glucose tolerance test.
Mean serum 25-hydroxyvitamin D increased from 39.9 +/- 1.5 (SEM) to 90.3 +/- 4.3 nmol/L (P < 0.0001) and mean serum parathyroid hormone decreased from 6.7 +/- 1.2 to 4.5 +/- 0.6 pmol/L (P = 0.055). There was no change in blood glucose mean of 0-120 min (6.1 +/- 0.3 before versus 6.2 +/- 0.3 mmol/L, P = 0.63) or insulin mean of 0-120 min (47.8 +/- 5.35 versus 48.9 +/- 5.22 mU/L, P = 0.67) concentrations, and no change in insulin sensitivity (Avignon's insulin sensitivity index [SiM], P = 0.97; insulin sensitivity index at 0 and 120 min [ISI(0,120)], P = 0.74; Quantitative Insulin Sensitivity Check Index [QUICKI], P = 0.88; homeostasis model assessment [HOMA], P = 0.99) after vitamin D treatment. Results did not differ between subjects, with and without, impaired glucose tolerance.
In adults without diabetes, correction of vitamin D deficiency is not associated with any effect on blood glucose or insulin concentrations or insulin sensitivity as assessed during an oral glucose tolerance test. These observations do not support an association between glucose/insulin homeostasis and vitamin D, at least in the short term.
我们研究了维生素D治疗对无糖尿病的维生素D缺乏个体的血糖、血清胰岛素和胰岛素敏感性的影响。
33名维生素D不足（血清25-羟基维生素D浓度≤50 nmol/L）且无糖尿病（12名糖耐量受损）的成年人，每隔2周口服两次100000 IU胆钙化醇。在首次给药前和第二次给药后2周，进行75 g口服葡萄糖耐量试验。测量血浆葡萄糖、血清胰岛素、25-羟基维生素D和甲状旁腺激素浓度，并根据口服葡萄糖耐量试验计算胰岛素敏感性。
血清25-羟基维生素D均值从39.9±1.5（标准误）升至90.3±4.3 nmol/L（P<0.0001），血清甲状旁腺激素均值从6.7±1.2降至4.5±0.6 pmol/L（P=0.055）。0至120分钟血糖均值无变化（给药前6.1±0.3 vs给药后6.2±0.3 mmol/L，P=0.63），0至120分钟胰岛素均值也无变化（47.8±5.35 vs 48.9±5.22 mU/L，P=0.67），维生素D治疗后胰岛素敏感性也无变化（阿维尼翁胰岛素敏感性指数[SiM]，P=0.97；0和120分钟时的胰岛素敏感性指数[ISI(0,120)]，P=0.74；定量胰岛素敏感性检查指数[QUICKI]，P=0.88；稳态模型评估[HOMA]，P=0.99）。糖耐量受损和未受损的受试者结果无差异。
在无糖尿病的成年人中，纠正维生素D缺乏对口服葡萄糖耐量试验期间评估的血糖、胰岛素浓度或胰岛素敏感性无任何影响。这些观察结果不支持葡萄糖/胰岛素稳态与维生素D之间的关联，至少在短期内如此。
